MediWound Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by MediWound Ltd. for the month of December 2023, with a specific reporting date of December 15, 2023. The filing discloses recent open market acquisitions of the Company's ordinary shares by select members of its board of directors, an executive officer, and the Chairman of the board of its largest shareholder, Clal Biotechnology Industries Ltd. ("CBI").
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes and Transactions
Between November 27 and December 15, 2023, the following individuals purchased a total of 10,500 ordinary shares of the Company through open market transactions:
- Mr. Nachum (Homi) Shamir, Chairman of the Company's board
- Messrs. David Fox and Shmeul (Milky) Rubinstein, board members
- Mr. Ofer Gonen, CEO of the Company
- Mr. Avi Fischer, Chairman of CBI's board
The average purchase price per share was $9.42. All transactions were conducted in adherence to the Company's insider trading policy.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report serves solely to disclose the aforementioned insider trading activity.
Key Facts for Investor Verification
- Total shares purchased by insiders: 10,500
- Average purchase price: $9.42 per share
- Transaction period: November 27, 2023, to December 15, 2023
- Compliance: Transactions adhered to the Company's insider trading policy
- Significant shareholder involvement: Includes the Chairman of Clal Biotechnology Industries Ltd., the Company's largest shareholder